Trichomonas: Common, Underdiagnosed, and Still Dependent on Outdated Pathways

Trichomonas vaginalis is one of the most common non-viral sexually transmitted infections globally. And yet, in many healthcare settings, it remains under-recognised, inconsistently tested for, and often missed.

This raises an important question:

Is the issue awareness — or is it how we’re testing?

A condition hiding in plain sight

Globally, trichomoniasis accounts for millions of infections each year. However, in the UK and many European settings, reported case numbers are relatively low.

This isn’t necessarily because the infection is rare.

More likely, it reflects a combination of:

• Limited routine testing
• High rates of asymptomatic infection
• Variation in diagnostic methods

In particular, men are rarely tested and often asymptomatic, creating a potential reservoir of undetected infection.

Testing in practice: a balance of access and accuracy

In many clinical settings, particularly sexual health services, testing pathways are shaped by a balance between what is ideal and what is practical.

Current guidance, such as that from British Association for Sexual Health and HIV, reflects this reality.

Microscopy (wet mount)

• Fast and accessible
• Provides immediate results
• Commonly used in symptomatic patients

However:

• Sensitivity is relatively low
• Results are operator-dependent
• Infections can be missed, particularly in low organism load or asymptomatic cases

NAAT (molecular testing)

• High sensitivity and specificity
• Effective in asymptomatic patients and men
• Considered the most accurate method

But:

• Typically lab-based
• Requires additional steps (sample transport, result delay)
• Not always accessible in all pathways

The gap between guidance and optimal detection

Importantly, this is not a case of poor practice.

Clinicians following current guidelines are often doing exactly what is recommended.

But those guidelines themselves reflect a compromise:

Accessibility vs accuracy

Which leads to a broader challenge:

• Some settings rely on methods that may miss cases
• Others have access to more accurate testing, but not always in real time
• Pathways vary significantly between services

The result?

Inconsistent detection — and therefore inconsistent outcomes.

The pathway problem

A recurring theme across healthcare is that diagnostics don’t operate in isolation — they sit within pathways.

And in the case of trichomonas, those pathways often involve:

• Symptom-based testing
• Multiple steps
• Potential delays between test and result

Each step introduces an opportunity for:

• Missed diagnosis
• Loss to follow-up
• Variation in care

Where next?

Improving trichomonas detection is not simply about introducing new tests.

It’s about addressing three key factors:

1. Consistency

Reducing variation in how and when patients are tested

2. Accessibility

Ensuring more sensitive methods are available within routine pathways

3. Timeliness

Linking testing more closely to clinical decision-making

Closing thought

Trichomonas is not a rare infection.

But in many cases, it behaves like one — because it isn’t consistently detected.

The challenge isn’t just clinical.

It’s structural.

And bridging that gap may depend on approaches that combine accuracy with accessibility and immediacy — bringing reliable testing closer to the point of care, where results can inform decisions in real time.